市場調査レポート

商品コード

1421685

重症筋無力症治療市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、診断別、治療別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

出版日: 2023年11月23日 | 発行: Polaris Market Research

| ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,250 667,845円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,250 824,985円

レポートPDFを20名様までご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 6,250 982,125円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Polaris Market Research社の最新調査によると、重症筋無力症治療の世界市場規模は2032年までに23億2,000万米ドルに達する見込みです。本レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

重症筋無力症は自己免疫性神経筋疾患であり、免疫系が神経と筋肉の接続を攻撃するために筋力低下や疲労を引き起こします。

重症筋無力症（MG）治療市場は、いくつかの要因により近年着実に成長しています。診断件数の増加、病気に対する理解の深まり、治療法の進歩などが挙げられます。製薬会社も研究開発に投資し、より有効で副作用の少ない革新的な治療法を導入しています。生物学的製剤や分子標的治療薬の出現により、より安全で効率的な治療法への需要が引き続き世界のMG治療市場の成長を牽引すると予想されます。

COVID-19の大流行は、重症筋無力症（MG）疾患市場に大きな影響を与えました。MGは、ヘルスケアシステムがCOVID-19患者に集中したため、診断と治療に遅れが生じ、課題に直面していました。しかし、パンデミックは遠隔医療と遠隔モニタリングの利用を加速させ、MG患者がウイルスへの曝露を最小限に抑えながら医療従事者と相談できる重要なツールを提供しました。製薬業界は、このような混乱にもかかわらず、MGの新規治療法の開発を続け、治療選択肢の改善への希望をもたらしています。

さらに、2021年6月にNational Library of Medicineに掲載された研究では、冠動脈疾患（CAD）が世界の健康に与える影響の大きさが強調されました。CADだけで年間約61万人が死亡しており、推定死亡者数の4人に1人を占め、米国における死亡原因の第1位となっています。CADの発症率が上昇するにつれ、この差し迫った医療ニーズに対処するための効果的な冠動脈ステント装置に対する需要が高まっています。その結果、この要因が予測期間を通じて冠動脈ステントの需要を促進すると予測されています。

重症筋無力症市場レポートハイライト

2022年、重症筋無力症市場においてIVIgセグメントが最大の売上シェアを占めました。免疫グロブリン静注療法（IVIg）には、健康なドナーから得た免疫グロブリン抗体の注入が含まれます。この医療処置は、免疫系を一時的に調整し、重症筋無力症（MG）の症状を管理する上で非常に有効であることが判明しています。
予測期間中、病院セグメントが最も高い市場シェアを占めました。病院薬局は、様々な薬剤の配布や塗布を通じて重症筋無力症（MG）の管理に重要な役割を果たしています。MGの症例が増加するにつれ、病院で治療を受ける患者が増え、病院薬局におけるMG特異的薬剤の需要が高まっています。
2022年には、北米が最大市場を占めました。重症筋無力症（MG）は北米で顕著な有病率を示しており、北米は治療において重要な位置を占めています。この地域の強固なヘルスケアインフラは、相当数の重症筋無力症患者の特定と管理を容易にし、製薬企業や研究者の関心を集めています。さらに、弾力的なヘルスケア償還の枠組みは、多くの高価なMG治療への適用を効果的に拡大し、患者にとってのアクセシビリティを高め、迅速な介入を促進しています。
アジア太平洋地域は、筋無力症治療市場において最も速い成長を占めています。同市場の成長を牽引しているのは、様々な要因であるが、特に官民両機関の協調的な取り組みが挙げられます。このような努力は、主に神経筋疾患の効果的な治療法の開発と普及に重点を置いています。さらに、教育キャンペーンや情報普及活動によって神経筋疾患に対する一般市民の意識が高まっていることも、市場の拡大に拍車をかけています。

重症筋無力症治療- 業界スナップショット
重症筋無力症治療市場力学
- 促進要因と機会
  - 世界中の治療法と治療選択肢の改善により市場の成長が促進される
  - ヘルスケアインフラ法案のインフレが市場の成長を促進
- 抑制要因と課題
  - 高額な治療費が市場の成長を妨げる
PESTLE分析
重症筋無力症治療業界の動向
バリューチェーン分析
COVID-19感染症の影響分析

第5章世界の重症筋無力症治療市場、薬剤クラス別

主な調査結果
イントロダクション
IVIg
モノクローナル抗体
免疫抑制剤
コリンエステラーゼ阻害剤
コルチコステロイド

第6章世界の重症筋無力症治療市場、診断別

主な調査結果
イントロダクション
血液検査
電気診断
エドロフォニウムテスト

第7章世界の重症筋無力症治療市場、治療別

主な調査結果
イントロダクション
手術
薬剤
HSCT

第8章世界の重症筋無力症治療市場、流通チャネル別

主な調査結果
イントロダクション
オンライン薬局
病院薬局
小売薬局

第9章世界の重症筋無力症治療市場、地域別

主な調査結果
イントロダクション
- 重症筋無力症治療市場評価、地域、2019-2032年
重症筋無力症治療市場-北米
- 北米：重症筋無力症治療市場、薬剤クラス別、2019～2032年
- 北米：重症筋無力症治療市場、流通チャネル別、2019～2032年
- 北米：重症筋無力症治療市場、診断別、2019～2032年
- 北米：重症筋無力症治療市場、治療別、2019～2032年
- 重症筋無力症治療市場-米国
- 重症筋無力症治療市場- カナダ
重症筋無力症治療市場- 欧州
- 欧州：重症筋無力症治療市場、薬剤クラス別、2019～2032年
- 欧州：重症筋無力症治療市場、流通チャネル別、2019～2032年
- 欧州：重症筋無力症治療市場、診断別、2019～2032年
- 欧州：重症筋無力症治療市場、治療別、2019～2032年
- 重症筋無力症治療市場- 英国
- 重症筋無力症治療市場- フランス
- 重症筋無力症治療市場- ドイツ
- 重症筋無力症治療市場- イタリア
- 重症筋無力症治療市場- スペイン
- 重症筋無力症治療市場- オランダ
- 重症筋無力症治療市場- ロシア
重症筋無力症治療市場- アジア太平洋
- アジア太平洋：重症筋無力症治療市場、薬剤クラス別、2019～2032年
- アジア太平洋：重症筋無力症治療市場、流通チャネル別、2019～2032年
- アジア太平洋：重症筋無力症治療市場、診断別、2019～2032年
- アジア太平洋：重症筋無力症治療市場、治療別、2019～2032年
- 重症筋無力症治療市場- 中国
- 重症筋無力症治療市場- インド
- 重症筋無力症治療市場- 日本
- 重症筋無力症治療市場- マレーシア
- 重症筋無力症治療市場- インドネシア
- 重症筋無力症治療市場- 韓国
重症筋無力症治療市場-中東およびアフリカ
- 中東およびアフリカ：重症筋無力症治療市場、薬剤クラス別、2019～2032年
- 中東およびアフリカ：重症筋無力症治療市場、流通チャネル別、2019～2032年
- 中東およびアフリカ：重症筋無力症治療市場、診断別、2019～2032年
- 中東およびアフリカ：重症筋無力症治療市場、治療別、2019～2032年
- 重症筋無力症治療市場- サウジアラビア
- 重症筋無力症治療市場- 南アフリカ
- 重症筋無力症治療市場- イスラエル
- 重症筋無力症治療市場-UAE
重症筋無力症治療市場-ラテンアメリカ
- ラテンアメリカ：重症筋無力症治療市場、薬剤クラス別、2019-2032年
- ラテンアメリカ：重症筋無力症治療市場、流通チャネル別、2019-2032年
- ラテンアメリカ：重症筋無力症治療市場、診断別、2019～2032年
- ラテンアメリカ：重症筋無力症治療市場、治療別、2019～2032年
- 重症筋無力症治療市場- メキシコ
- 重症筋無力症治療市場- ブラジル
- 重症筋無力症治療市場- アルゼンチン

第10章競合情勢

拡張と買収の分析
- 拡大
- 買収
提携/協業/合意/公開

第11章企業プロファイル

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
Bristol-Myers Squibb Company（now part of Bristol Myers Squibb）
Grifols, S.A.
Mylan N.V.（now part of Viatris Inc.）
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Roche Holdings AG（including its subsidiary, Genentech）
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

図表

List of Tables

Table 1 Global Myasthenia Gravis Disease Treatment Market, by Drug Class, by Region, 2019-2032 (USD Billion)
Table 2 Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
Table 3 Global Myasthenia Gravis Disease Treatment Market, by Treatment, by Region, 2019-2032 (USD Billion)
Table 4 Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
Table 5 Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
Table 6 North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 7 North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 8 North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 9 North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 10 U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 11 U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 12 U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 13 U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 14 Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 15 Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 16 Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 17 Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 18 Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 19 Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 20 Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 21 Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 22 Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 23 Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 24 Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 25 Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 26 France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 27 France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 28 France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 29 France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 30 UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 31 UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 32 UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 33 UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 34 Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 35 Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 36 Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 37 Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 38 Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 39 Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 40 Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 41 Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 42 Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 43 Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 44 Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 45 Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 46 Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 47 Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 48 Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 49 Russia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 50 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 51 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 52 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 53 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 54 China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 55 China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 56 China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 57 China: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 58 Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 59 Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 60 Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 61 Japan: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 62 India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 63 India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 64 India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 65 India: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 66 Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 67 Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 68 Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 69 Indonesia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 70 Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 71 Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 72 Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 73 Malaysia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 74 South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 75 South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 76 South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 77 South Korea: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 78 Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 79 Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 80 Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 81 Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 82 Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 83 Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 84 Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 85 Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 86 Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 87 Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 88 Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 89 Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 90 Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 91 Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 92 Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 93 Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 94 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 95 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 96 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 97 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 98 UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 99 UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 100 UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 101 UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 102 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 103 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 104 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 105 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 106 South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 107 South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 108 South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 109 South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
Table 110 Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
Table 111 Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
Table 112 Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
Table 113 Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

Figure 1. Global Myasthenia Gravis Disease Treatment Market, 2019-2032 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
Figure 4. Market by Geography
Figure 5. Porter's Five Forces
Figure 6. Market by Drug Class
Figure 7. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2021 & 2030 (USD Billion)
Figure 8. Market by Distribution Channel
Figure 9. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2021 & 2030 (USD Billion)
Figure 10. Market by Diagnosis
Figure 11. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2021 & 2030 (USD Billion)
Figure 12. Market by Treatment
Figure 13. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2021 & 2030 (USD Billion)

Product Code: PM4026

The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.

The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.

The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.

Myasthenia Gravis Disease Market Report Highlights

In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).

The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.

In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.

The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.

The global key market players include: AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

IVIg
Monoclonal Antibodies
Immunosuppressants
Cholinesterase Inhibitors
Corticosteroids

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

Blood Tests
Electrodiagnosis
Edrophonium Test

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

Surgery
Medication
HSCT

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Treatment Market Insights

4.1. Myasthenia Gravis Disease Treatment - Industry Snapshot
4.2. Myasthenia Gravis Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
  - 4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High treatment cost will hamper on the market growth
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Myasthenia Gravis Disease Treatment Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
5.3. IVIg
- 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
5.4. Monoclonal Antibodies
- 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
5.5. Immunosuppressants
- 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
5.6. Cholinesterase Inhibitors
- 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
5.7. Corticosteroids
- 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
6.3. Blood Tests
- 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
6.4. Electrodiagnosis
- 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
6.5. Edrophonium Test
- 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
7.3. Surgery
- 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
7.4. Medication
- 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
7.5. HSCT
- 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
8.3. Online Pharmacies
- 8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
8.4. Hospital Pharmacies
- 8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
8.5. Retail Pharmacies
- 8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

9.1. Key findings
9.2. Introduction
- 9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
9.3. Myasthenia Gravis Disease Treatment Market - North America
- 9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.3.5. Myasthenia Gravis Disease Treatment Market - U.S.
  - 9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.3.6. Myasthenia Gravis Disease Treatment Market - Canada
  - 9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
9.4. Myasthenia Gravis Disease Treatment Market - Europe
- 9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.5. Myasthenia Gravis Disease Treatment Market - UK
  - 9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.6. Myasthenia Gravis Disease Treatment Market - France
  - 9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.7. Myasthenia Gravis Disease Treatment Market - Germany
  - 9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.8. Myasthenia Gravis Disease Treatment Market - Italy
  - 9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.9. Myasthenia Gravis Disease Treatment Market - Spain
  - 9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.10. Myasthenia Gravis Disease Treatment Market - Netherlands
  - 9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.11. Myasthenia Gravis Disease Treatment Market - Russia
  - 9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
9.5. Myasthenia Gravis Disease Treatment Market - Asia Pacific
- 9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.5. Myasthenia Gravis Disease Treatment Market - China
  - 9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.6. Myasthenia Gravis Disease Treatment Market - India
  - 9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.7. Myasthenia Gravis Disease Treatment Market - Japan
  - 9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.8. Myasthenia Gravis Disease Treatment Market - Malaysia
  - 9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.9. Myasthenia Gravis Disease Treatment Market - Indonesia
  - 9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.10. Myasthenia Gravis Disease Treatment Market - South Korea
  - 9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
9.6. Myasthenia Gravis Disease Treatment Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.5. Myasthenia Gravis Disease Treatment Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.6. Myasthenia Gravis Disease Treatment Market - South Africa
  - 9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.7. Myasthenia Gravis Disease Treatment Market - Israel
  - 9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.8. Myasthenia Gravis Disease Treatment Market - UAE
  - 9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
9.7. Myasthenia Gravis Disease Treatment Market - Latin America
- 9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.5. Myasthenia Gravis Disease Treatment Market - Mexico
  - 9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.6. Myasthenia Gravis Disease Treatment Market - Brazil
  - 9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.7. Myasthenia Gravis Disease Treatment Market - Argentina
  - 9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  - 9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  - 9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Alexion Pharmaceuticals, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Grifols, S.A.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Mylan N.V. (now part of Viatris Inc.)
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Novartis AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Pfizer Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Regeneron Pharmaceuticals, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Roche Holdings AG (including its subsidiary, Genentech)
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
11.11. Takeda Pharmaceutical Company Limited
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
11.12. Teva Pharmaceutical Industries Ltd.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development

重症筋無力症治療市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、診断別、治療別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

重症筋無力症市場レポートハイライト

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界の重症筋無力症治療市場の洞察

第5章世界の重症筋無力症治療市場、薬剤クラス別

第6章世界の重症筋無力症治療市場、診断別

第7章世界の重症筋無力症治療市場、治療別

第8章世界の重症筋無力症治療市場、流通チャネル別

第9章世界の重症筋無力症治療市場、地域別

第10章競合情勢

第11章企業プロファイル

List of Tables

List of Figures

Myasthenia Gravis Disease Market Report Highlights

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Myasthenia Gravis Disease Treatment Market Insights

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

10. Competitive Landscape

11. Company Profiles

重症筋無力症治療市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、診断別、治療別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

重症筋無力症市場レポートハイライト

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の重症筋無力症治療市場の洞察

第5章 世界の重症筋無力症治療市場、薬剤クラス別

第6章 世界の重症筋無力症治療市場、診断別

第7章 世界の重症筋無力症治療市場、治療別

第8章 世界の重症筋無力症治療市場、流通チャネル別

第9章 世界の重症筋無力症治療市場、地域別

第10章 競合情勢

第11章 企業プロファイル

List of Tables

List of Figures

Myasthenia Gravis Disease Market Report Highlights

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Myasthenia Gravis Disease Treatment Market Insights

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

10. Competitive Landscape

11. Company Profiles

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界の重症筋無力症治療市場の洞察

第5章世界の重症筋無力症治療市場、薬剤クラス別

第6章世界の重症筋無力症治療市場、診断別

第7章世界の重症筋無力症治療市場、治療別

第8章世界の重症筋無力症治療市場、流通チャネル別

第9章世界の重症筋無力症治療市場、地域別

第10章競合情勢

第11章企業プロファイル